{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T10:41:53Z","timestamp":1693737713805},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010878","name":"AbbVie Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Kaohsiung J of Med Scie"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C virus (HCV) infection is the leading cause of chronic liver diseases worldwide. Monitoring its epidemiology, diagnosis, and treatment patterns are important for the management of patients with chronic HCV infection from both individual and public health perspectives. The MOSAIC study was an observational study conducted in 20 countries, including Taiwan; its primary objective was to describe epidemiology and treatment initiation patterns in patients seeking HCV care. Of the 111 chronic HCV patients enrolled from Taiwan, 58 (52.3%) had not previously received treatment. HCV genotype 1 was reported in 58 (52.3%) patients, of whom the majority (n = 47; 81.0%) were identified as having subtype 1b. Sixty\u2010two (55.9%) patients had HCV RNA level\u2009&gt;\u2009800\u2009000\u2009IU\/mL. Liver cirrhosis was found in 35 (29.3%) patients and was more prevalent in patients who previously received treatment (71.0%). Interferon (IFN)\u2010based treatment was started within 12\u2009weeks from study inclusion in 12 (10.8%) patients, of whom 11 (91.7%) who had not previously received treatment. Anti\u2010HCV treatment was not recommended by physicians in 70 (71.4%) and was refused by 23 (23.5%) patients. The MOSAIC study provides data on the epidemiology of HCV infection and IFN\u2010based treatment decision patterns in Taiwan. Further studies are needed to observe the impact of IFN\u2010free treatment on the treatment selection pattern.<\/jats:p>","DOI":"10.1002\/kjm2.12317","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T14:10:45Z","timestamp":1603375845000},"page":"245-252","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The <scp>MOSAIC<\/scp> study"],"prefix":"10.1002","volume":"37","author":[{"given":"Ming\u2010Lung","family":"Yu","sequence":"first","affiliation":[{"name":"Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center Kaohsiung Medical University Hospital  Kaohsiung Taiwan"},{"name":"School of Medicine and Hepatitis Research Center, College of Medicine, and Center for Cancer Research and Center for Liquid Biopsy Kaohsiung Medical University  Kaohsiung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei\u2010Lun","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine Kaohsiung Veterans General Hospital  Kaohsiung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi\u2010Jen","family":"Chu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine Taipei Veterans General Hospital  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia\u2010Horng","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hepatitis Research Center National Taiwan University Hospital  Taipei Taiwan"},{"name":"Graduate Institute of Clinical Medicine College of Medicine, National Taiwan University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"World Health Organization.Global hepatitis report 2017. Available from:http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/. Accessed May 6 2020."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"e_1_2_6_4_1","unstructured":"World Health Organization.Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection 2018. Available from:https:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2018\/en\/. Accessed May 6 2020."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27831"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i32.11033"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i34.7824"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139687"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9629-x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2013.08.001"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2015.09.006"},{"key":"e_1_2_6_13_1","unstructured":"Centers for Disease Control (Taiwan) \u2010 National Disease Statistics System.Acute hepatitis C. Available from:https:\/\/www.cdc.gov.tw\/En. Accessed May 6 2020."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936115585942"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14275"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2015.06.012"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy648"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12086"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2017.10.001"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000606"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61991-3"},{"key":"e_1_2_6_24_1","unstructured":"World Health Organization.Regional action plan for viral hepatitis in south\u2010east Asia: 2016\u20132021. Available fromhttps:\/\/apps.who.int\/iris\/handle\/10665\/258735. Accessed May 6 2020."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2015.30.4.423"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.04.003"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.04.002"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2016.10.008"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2017.02.013"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0921"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13747"},{"key":"e_1_2_6_32_1","unstructured":"NHI Taiwan.The coverage of oral drug treatments for Hepatitis C in the National Health Insurance is approved with conditions by the NHI Supervisory Board.2016. Available fromhttps:\/\/www.nhi.gov.tw\/english\/News_Content.aspx?n=996D1B4B5DC48343&sms=F0EAFEB716DE7FFA&s=37B41539382B84BA. Accessed May 6 2020."},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02313-y"},{"key":"e_1_2_6_35_1","unstructured":"American Association for the Study of Liver Diseases and Infectious Disease Society of America.HCV guidance: recommendations for testing managing and treating hepatitis C. Available fromhttps:\/\/www.hcvguidelines.org. Accessed May 6 2020."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000690"}],"container-title":["The Kaohsiung Journal of Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/kjm2.12317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/kjm2.12317","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/kjm2.12317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:33:51Z","timestamp":1693701231000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/kjm2.12317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1002\/kjm2.12317"],"URL":"https:\/\/doi.org\/10.1002\/kjm2.12317","archive":["Portico"],"relation":{},"ISSN":["1607-551X","2410-8650"],"issn-type":[{"value":"1607-551X","type":"print"},{"value":"2410-8650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"2020-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}